



MAGLUMI® Digoxin (CLIA)

INTENDED USE

The kit is an *in vitro* chemiluminescence immunoassay for the quantitative determination of Digoxin in human serum and plasma using the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer and Biolumi series Integrated System, and the assay is used for an aid in the diagnosis and treatment of digoxin overdose and in monitoring levels of digoxin to ensure appropriate therapy.

SUMMARY

Digoxin is a cardiac glycoside derived from *Digitalis lanata*. It has been heavily employed when treating a number of heart problems, including congestive heart failure, atrial fibrillation or flutter, and certain cardiac arrhythmias¹. Digoxin's primary mechanism of action is the ability to inhibit membrane bound alpha subunits of Na⁺/K⁺-ATPase (sodium pump). This inhibition promotes sodium-calcium exchange, which increases the intracellular calcium concentration that is available to the contractile proteins, resulting in an increase in the force of myocardial contraction². Beneficial effects include improvement in cardiac index, decrease in left ventricular filling pressure, and fall in systemic vascular resistance³. Digoxin also has important parasympathetic effects, particularly on the atrioventricular node⁴. The therapeutic range of digoxin usually is considered as 0.8–2.0 ng/mL, but there is a substantial overlap between therapeutic and toxic concentrations. Overt digoxin toxicity is commonly associated with serum digoxin levels >2 ng/mL⁴. The concomitant use of drugs such as quinidine, verapamil, spironolactone, flecainide and amiodarone can increase serum digoxin levels and increase the risk of digoxin toxicity⁵. Toxicity may occur with accidental or intentional overdose and can manifest as cardiac or extracardiac manifestations⁶. The clinical side effects associated with high concentrations of digoxin in serum include paroxysmal atrial tachycardia with block, atrioventricular block, ventricular ectopy (e.g., bigeminy), and rarely, atrial arrhythmia⁷. Because these effects resemble the clinical condition for which the drug is administered, and because the drug has a low therapeutic ratio (a small difference between therapeutic and tissue toxic levels), it is recommended that the serum concentration of digoxin or digitoxin be monitored to determine if the drug dose needs to be increased (if the patient is subtherapeutic) or if a possible overdose needs to be treated (if the serum concentration of the drug is above the therapeutic range)⁷.

Other clinical and emergency situations in which serum digoxin monitoring is recommended include: (a) in cases of digitalis intoxication, to determine the amount of antidote (Fab fragment) needed; (b) in suspected poisoning by ingestion of plants such as oleandrin, to confirm the presence of digitalis-like poisons; (c) in patients with decreased renal function, to adjust digoxin dosage; and (d) in cases when other drugs known to interact with digoxin pharmacokinetics (e.g., quinidine, amiodarone, verapamil) are coadministered⁷.

TEST PRINCIPLE

Competitive chemiluminescence immunoassay.

The sample, buffer, magnetic microbeads coated with Digoxin monoclonal antibody, ABEI labeled with Digoxin antigen conjugate are mixed thoroughly and incubated. Digoxin present in the sample compete with Digoxin antigen labeled with ABEI for binding Digoxin monoclonal antibody immobilized on the magnetic microbeads, forming immuno-complexes. After precipitation in a magnetic field, the supernatant is decanted and then a wash cycle is performed. Subsequently, the Starter 1+2 are added to initiate a chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is inversely proportional to the concentration of Digoxin present in the sample.

REAGENTS

Kit Contents

Component	Description	100 tests/kit	50 tests/kit	30 tests/kit
Magnetic Microbeads	Magnetic microbeads coated with Digoxin monoclonal antibody (~4.00 µg/mL) in PBS buffer, NaNa ₃ (<0.1%).	2.5 mL	1.5 mL	1.0 mL
Calibrator Low	A low concentration of Digoxin antigen, BSA, NaNa ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Calibrator High	A high concentration of Digoxin antigen, BSA, NaNa ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Buffer	Tris-HCl buffer, NaNa ₃ (<0.1%).	5.5 mL	3.5 mL	2.7 mL
ABEI Label	ABEI labeled with Digoxin antigen conjugate (~83.3 ng/mL) in PBS buffer, NaNa ₃ (<0.1%).	6.5 mL	4.0 mL	3.0 mL
Control 1	A low concentration of Digoxin antigen (1.50 ng/mL), BSA, NaNa ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Control 2	A high concentration of Digoxin antigen (5.00 ng/mL), BSA, NaNa ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
All reagents are provided ready-to-use.				

Warnings and Precautions

- For *in vitro* diagnostic use.
- For professional use only.
- Exercise the normal precautions required for handling all laboratory reagents.
- Personal protective measures should be taken to prevent any part of the human body from contacting samples, reagents, and controls, and should comply with local operating requirements for the assay.
- A skillful technique and strict adherence to the package insert are necessary to obtain reliable results.
- Do not use kit beyond the expiration date indicated on the label.
- Do not interchange reagent components from different reagents or lots.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- All waste associated with biological samples, biological reagents and disposable materials used for the assay should be considered potentially infectious and should be disposed of in accordance with local guidelines.
- This product contains sodium azide. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. Immediately after disposal, flush with a large volume of water to prevent azide build-up. For additional information, see Safety Data Sheets available for professional user on request.

Note: If any serious incident has occurred in relation to the device, please report to Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) or our authorized representative and the competent authority of the Member State in which you are established.

Reagent Handling

- To avoid contamination, wear clean gloves when operating with a reagent kit and sample. When handling reagent kit, replace the gloves that have been in contact with samples, since introduction of samples will result in unreliable results.
- Do not use kit in malfunction conditions; e.g., the kit leaking at the sealing film or elsewhere, obviously turbid or precipitation is found in reagents (except for Magnetic Microbeads) or control value is out of the specified range repeatedly. When kit in malfunction conditions, please contact Snibe or our authorized distributor.
- To avoid evaporation of the liquid in the opened reagent kits in refrigerator, it is recommended that the opened reagent kits to be sealed with reagent seals contained within the packaging. The reagent seals are single use, and if more seals are needed, please contact Snibe or our authorized distributor.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts and have no effect on assay efficacy.
- Use always the same analyzer for an opened reagent integral.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- For further information about the reagent handling during system operation, please refer to Analyzer Operating Instructions.

Storage and Stability

- Do not freeze the integral reagents.
- Store the reagent kit upright to ensure complete availability of the magnetic microbeads.
- Protect from direct sunlight.

Stability of the Reagents	
Unopened at 2-8°C	until the stated expiration date
Opened at 2-8°C	6 weeks



0123



130257002M: 100 tests/kit
130657002M: 50 tests/kit
130757002M: 30 tests/kit

On-board	4 weeks
Stability of Controls	
Unopened at 2-8°C	until the stated expiration date
Opened at 10-30°C	6 hours
Opened at 2-8°C	6 weeks
Frozen at -20°C	3 months
Frozen and thawed cycles	no more than 3 times

SPECIMEN COLLECTION AND PREPARATION

Specimen Types

Only the specimens listed below were tested and found acceptable.

Specimen Types	Collection Tubes
Serum	Tubes without additive/accessory, or tubes containing clot activator or clot activator with gel.
Plasma	K2-EDTA

- The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. Follow tube manufacturers' instructions carefully when using collection tubes.

Specimen Conditions

- Note the time of collection, just before the next dose, or no less than six hours after the administration of digoxin, to avoid misleadingly high digoxin results.
- Do not use heat-inactivated samples or grossly hemolyzed/hyperlipidaemia specimens and specimens with obvious microbial contamination.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some serum specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the serum specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results.
- Samples must be free of fibrin and other particulate matter.
- To prevent cross contamination, use of disposable pipettes or pipette tips are recommended.

Preparation for Analysis

- Inspect all specimens for foam. Remove foam with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.
- Frozen specimens must be completely thawed before mixing. Mix thawed specimens thoroughly by low speed vortexing or by gently inverting. Visually inspect the specimens. If layering or stratification is observed, mix until specimens are visibly homogeneous. If specimens are not mixed thoroughly, inconsistent results may be obtained.
- Specimens should be free of fibrin, red blood cells, or other particulate matter. Such specimens may give reliable results and must be centrifuged prior to testing. Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- The sample volume required for a single determination of this assay is 40 µL.

Specimen Storage

Specimens removed from the separator, red blood cells or clot may be stored up to 48 hours at 10-30°C or 14 days at 2-8°C, or 6 months frozen at -20°C. Frozen specimens subjected to up to 2 freeze/thaw cycles have been evaluated.

Specimen Shipping

- Package and label specimens in compliance with applicable local regulations covering the transport of clinical specimens and infectious substances.
- Do not exceed the storage limitations listed above.

Specimen Dilution

- Further dilution is not necessary due to the broad measuring range.

PROCEDURE

Materials Provided

Digoxin (CLIA) assay, control barcode labels.

Materials Required (But Not Provided)

- General laboratory equipment.
- Fully-auto chemiluminescence immunoassay analyzer Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X8, MAGLUMI X3, MAGLUMI X6 or Integrated System Biolumi 8000, Biolumi CX8.
- Additional accessories of test required for the above analyzers include Reaction Module, Starter 1+2, Wash Concentrate, Light Check, Tip, and Reaction Cup. Specific accessories and accessories' specification for each model refer to corresponding Analyzer Operating Instructions.
- Please use accessories specified by Snibe to ensure the reliability of the test results.

Assay Procedure

Preparation of the Reagent

- Take the reagent kit out of the box and visually inspect the integral vials for leaking at the sealing film or elsewhere. If there is no leakage, please tear off the sealing film carefully.
- Open the reagent area door; hold the reagent handle to get the RFID label close to the RFID reader (for about 2s); the buzzer will beep; one beep sound indicates successful sensing.
- Keeping the reagent straight insert to the bottom along the blank reagent track.
- Observe whether the reagent information is displayed successfully in the software interface, otherwise repeat the above two steps.
- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are totally resuspended homogenous prior to use.

Assay Calibration

- Select the assay to be calibrated and execute calibration operation in reagent area interface. For specific information on ordering calibrations, refer to the calibration section of Analyzer Operating Instructions.
- Execute recalibration according to the calibration interval required in this package insert.

Quality Control

- When new lot used, check or edit the quality control information.
- Scan the control barcode, choose corresponding quality control information and execute testing. For specific information on ordering quality controls, refer to the quality control section of the Analyzer Operating Instructions.

Sample Testing

- After successfully loading the sample, select the sample in interface and edit the assay for the sample to be tested and execute testing. For specific information on ordering patient specimens, refer to the sample ordering section of the Analyzer Operating Instructions.

To ensure proper test performance, strictly adhere to Analyzer Operating Instructions.

Calibration

Traceability: This method has been standardized against the Snibe internal reference standard.

Test of assay specific calibrators allows the detected relative light unit (RLU) values to adjust the master curve.

Recalibration is recommended as follows:

- Whenever a new lot of Reagent or Starter 1+2 is used.
- Every 28 days.
- The analyzer has been serviced.

- Control values lie outside the specified range.

Quality Control

Controls are recommended for the determination of quality control requirements for this assay and should be run in singlicate to monitor the assay performance. Refer to published guidelines for general quality control recommendations, for example Clinical and Laboratory Standards Institute (CLSI) Guideline C24 or other published guidelines⁸.

Quality control is recommended once per day of use, or in accordance with local regulations or accreditation requirements and your laboratory’s quality control procedures, quality control could be performed by running the Digoxin assay:

- Whenever the kit is calibrated.
- Whenever a new lot of Starter 1+2 or Wash Concentrate is used.

Controls are only applicable with MAGLUMI and Biolumi systems and only used matching with the same top seven LOT numbers of corresponding reagents. For each target value and range refer to the label.

The performance of other controls should be evaluated for compatibility with this assay before they are used. Appropriate value ranges should be established for all quality control materials used.

Control values must lie within the specified range, whenever one of the controls lies outside the specified range, calibration should be repeated and controls retested. If control values lie repeatedly outside the predefined ranges after successful calibration, patient results must not be reported and take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the package insert.
- If necessary, contact Snibe or our authorized distributors for assistance.

If the controls in kit are not enough for use, please order Digoxin (CLIA) Controls (REF: 160201487MT) from Snibe or our authorized distributors for more.

RESULTS

Calculation

The analyzer automatically calculates the Digoxin concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in ng/mL. For further information please refer to the Analyzer Operating Instructions.

Conversion factors: nmol/L x 0.78 = ng/mL
ng/mL x 1.28 = nmol/L

Interpretation of Results

The optimal cut-off of the Digoxin assay was obtained by testing 436 nontoxic patients after taking medicine in China, 156 toxic patients after taking medicine in China.

- Samples with digoxin concentration ≤2.0 ng/mL should be considered nontoxic.
- Samples with digoxin concentration >2.0 ng/mL should be considered toxic.

By testing 436 nontoxic patients after taking medicine in China, gave the following expected therapeutic range:

Therapeutic range: 0.9-2.0 ng/mL (2.5th-97.5th percentiles).

LIMITATIONS

- Results should be used in conjunction with patient’s medical history, clinical examination and other findings.
- If the Digoxin results are inconsistent with clinical evidence, additional testing is needed to confirm the result.
- The assay is mainly used in monitoring levels of patients using digoxin to ensure appropriate therapy.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits which employ mouse monoclonal antibodies^{9,10}. Additional information may be required for diagnosis.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with *in vitro* immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed¹¹.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.
- The presence of endogenous digoxin-like immunoreactive factors (DLIF) has been reported in the serum of patients with renal and hepatic failure, and in newborns and women in the third trimester of pregnancy¹². These factors can result in falsely elevated digoxin results in a number of commercially available immunoassays.
- In cases of overdosage, specimens should be obtained before administering digoxin immune Fab antidote preparations since these can be expected to interfere with any digoxin immunoassay procedure.

SPECIFIC PERFORMANCE CHARACTERISTICS

Representative performance data are provided in this section. Results obtained in individual laboratories may vary.

Precision

Precision was determined using the assay, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): duplicates at two independent runs per day for 5 days at three different sites using three lots of reagent kits (n =180). The following results were obtained:

Sample	Mean (ng/mL) (n=180)	Within-Run		Between-Run		Reproducibility	
		SD (ng/mL)	%CV	SD (ng/mL)	%CV	SD (ng/mL)	%CV
Serum Pool 1	0.930	0.027	2.90	0.015	1.61	0.040	4.30
Serum Pool 2	1.943	0.041	2.11	0.024	1.24	0.066	3.40
Serum Pool 3	10.234	0.138	1.35	0.113	1.10	0.272	2.66
Plasma Pool 1	0.885	0.028	3.16	0.012	1.36	0.041	4.63
Plasma Pool 2	1.986	0.052	2.62	0.027	1.36	0.073	3.68
Plasma Pool 3	9.791	0.146	1.49	0.091	0.93	0.212	2.17
Control 1	1.523	0.038	2.50	0.027	1.77	0.063	4.14
Control 2	4.934	0.103	2.09	0.040	0.81	0.177	3.59

Linear Range

0.200-50.0 ng/mL (defined by the Limit of Quantitation and the maximum of the master curve).

Reportable Interval

0.150-50.0 ng/mL (defined by the Limit of Detection and the maximum of the master curve).

Analytical Sensitivity

Limit of Blank (LoB) =0.070 ng/mL.

Limit of Detection (LoD) =0.150 ng/mL.

Limit of Quantitation (LoQ) =0.200 ng/mL.

Analytical Specificity

Interference

Interference was determined using the assay, three samples containing different concentrations of analyte were spiked with potential endogenous and exogenous interferents in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Interference	No interference up to	Interference	No interference up to
Bilirubin	66 mg/dL	Canrenic acid	50000 ng/mL
Hemoglobin	1000 mg/dL	Canrenone	1000 ng/mL
Intralipid	3000 mg/dL	Prednisolone	100000 ng/mL
HAMA	40 ng/mL	Prednisone	5000 ng/mL
Rheumatoid factor	1630 IU/mL	Quabain	5000 ng/mL

ANA	398 AU/mL	Quinidine	5000 ng/mL
Human albumin	7 g/dL	17α-Hydroxy Progesterone	5000 ng/mL
Cholesterol	400 mg/dL	6-Dehydrocortisol	100 ng/mL
K2-EDTA	22.75 μmol/mL	Spironolactone	100000 ng/mL
Biotin	0.5 mg/dL		

Cross-Reactivity

Cross-reactivity was determined using the assay, three samples containing different concentrations of analyte were spiked with potential cross-reactant in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Cross-reactant	No interference up to	Cross-reactant	No interference up to
Estradiol	50 ng/mL	DHEA	5000 ng/mL
Estriol	10600 ng/mL	Corticosterone	100000 ng/mL
Cortisol	10000 ng/mL	Aldosterone	100 ng/mL
Progesterone	10500 ng/mL	Digitoxin	500 ng/mL
Testosterone	9500 ng/mL		

Method Comparison

A comparison of the Digoxin assay with a commercially available immunoassay, gave the following correlations (ng/mL):

Number of samples measured: 118

Passing-Bablok: y=1.0099x-0.0025, r=0.978.

The clinical specimen concentrations were between 0.21 and 49.84 ng/mL.

REFERENCES

- Patocka J, Nepovimova E, Wu W, et al. Digoxin: Pharmacology and toxicology—A review [J]. Environmental Toxicology and Pharmacology, 2020, 79: 103400.
- Gheorghiade M, Adams K F, Colucci W S. Digoxin in the Management of Cardiovascular Disorders[J]. Circulation, American Heart Association, 2004, 109(24): 2959–2964.
- Dec G W. Digoxin remains useful in the management of chronic heart failure[J]. Medical Clinics, Elsevier, 2003, 87(2): 317–337.
- Yancy C W, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure[J]. Journal of the American College of Cardiology, American College of Cardiology Foundation, 2013, 62(16): e147–e239
- Dasgupta A. Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances[J]. Toxicological Reviews, 2006, 25(4): 273–281.
- Thacker D, Sharma J. Digoxin toxicity[J]. Clinical pediatrics, 2007, 46(3): 276-279.
- Valdes Jr R, Jortani S A, Gheorghiade M. Standards of laboratory practice: cardiac drug monitoring[J]. Clinical chemistry, 1998, 44(5): 1096-1109.
- CLSI. Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
- Robert W. Schroff, Kenneth A. Foon, Shannon M. Beatty, et al. Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy[J]. Cancer Research, 1985, 45(2):879-885.
- Primus F J, Kelley E A, Hansen H J, et al. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy[J]. Clinical Chemistry, 1988, 34(2):261-264.
- Boscato L M, Stuart M C. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34(1):27-33.
- Valdes R Jr. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985;9:1525-1532.

SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
	Temperature limit (Store at 2-8°C)		Use-by date
	Contains sufficient for<n> tests		Keep away from sunlight
	This way up		Authorized representative in the European Community
	<i>In vitro</i> diagnostic medical device		Kit component
	Catalogue number		Batch code
	CE marking with notified body ID number		

MAGLUMI® and Biolumi® are trademarks of Snibe. All other product names and trademarks are the property of their respective owners.

Summary of safety and performance is available at Eudamed.

	Shenzhen New Industries Biomedical Engineering Co., Ltd. No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China Tel: +86-755-21536601 Fax:+86-755-28292740
	Shanghai International Holding Corp. GmbH (Europe) Eiffestrasse 80, 20537 Hamburg, Germany Tel: +49-40-2513175 Fax: +49-40-255726